Research
Mitochondria-Nuclear Crosstalk in Cancer
Our lab use transmitochondrial cybrid models (comparing different mitochondria under a common defined nuclear background) and multiple OMICs approaches to discover mitochondria-nuclear crosstalk and mitochondria-regulated oncopathways in metastatic cancer. Discoveries from cybrids are then validated using cell lines, patient-derived xenograft (PDX) models and clinical tissues from cancer patients. We use metabolic inhibitors to disturb metabolic flexibility to overcome resistance to anticancer therapy.
Hybrid Metabolic Phenotype in Cancer
Many cancer cells maintain hybrid metabolic status to use both oxidative phosphorylation and glycolysis for rapid tumor progression. We have recently shown that metastatic cancer cells can acquire a hybrid (glycolysis & OXPHOS) metabolic phenotype. Hybrid metabolic status allows cancer cells to utilize both glycolysis and OXPHOS for energy production and biomass synthesis and achieve metabolic plasticity to survive under hostile environments during metastatic progression.
Three-diementional (3D) Cell Growth and Bioimaging
In collaboration with material science researchers, Kaipparettu lab developed and validated nanoscale material-based bioimaging systems. We also develop economic materials for the three-dimensional (3D) cell growth.
Nano particle based systems for bioimaging
